The Re2O skin booster is a procedure that injects human acellular dermal matrix (hADM), made by removing cells from donated human skin and processing it finely enough to inject. Its starting point differs from a stem-cell procedure that places living cells.
The first question that splits the consultation is not a ranking of effects, but what goes into the syringe today. Processing of the raw material is covered in the Re2O raw-material guide, and the principle of support material inside the skin is covered in the ECM booster guide.
3-line summary
1. Re2O is a skin booster that injects finely processed donated dermis from which the cells have been removed.
2. The published human trial mixed Re2O with hyaluronic acid, saline, and an anesthetic, and mild redness and swelling settled without treatment.
3. In consultation, first confirm the product name, mixed ingredients, session count, and pregnancy, infection, and medications.
What goes into the syringe
Under the same name, the injected material differs by product. The manufacturer's product information introduces Re2O as 150mg of particulate acellular allogeneic dermis. It is tissue in which collagen, elastin, and proteins that make up the extracellular matrix (ECM)—the net inside the skin—remain. According to reports, the original developer is L&C Bio, and the supplier in Korea is Humedix.
In Korea it is a product managed as human tissue. Donor screening and processing records are confirmed during consultation together with the product documents. Points to ask before using a human-derived material are set out separately in the consultation guide for human tissue-derived materials.
Flow on the day of treatment
After reviewing the skin, treatment history, and medications in consultation, anesthesia is applied and the material is placed in the dermis. The published human trial targeted the mid-dermis for injection. Same-day duration and session guidance can be confirmed on the Re2O treatment overview.
| Step | What is done on the day |
|---|---|
| Consultation | Skin condition, recent facial procedures, medications, and allergies are confirmed. |
| Anesthesia | Topical cream anesthesia is often used, and the trial formulation also contained an anesthetic. |
| Injection | It is placed in the dermis. What is actually mixed in the syringe is matched against the table below. |
| Immediately after | Redness and swelling are checked, and when to resume washing, makeup, and exercise follows the written instructions given that day. |
The formulation used in the trial and the formulation you would receive today
What the human trial compared was a formulation that mixed Re2O with a hyaluronic acid skin booster, saline, and an anesthetic; the opposite side received hyaluronic acid alone. In the same paper, one author served as an advisor on the manufacturer's product development, and the test article was provided by the manufacturer.
| Item | Published human trial | What to match in consultation |
|---|---|---|
| Syringe contents | Re2O mixed with hyaluronic acid, saline, and an anesthetic | Today's actual mixed ingredients |
| Layer injected | Mid-dermis, automatic injector | Device used and depth |
| Observation period | About five months after treatment | Later follow-up schedule |
※ The trial was small and used a mixed formulation. Adverse reactions after five months are outside the scope of this data. If today's mixed composition differs from the trial, recovery is not mapped onto that observation period as-is.
How Re2O sits alongside Rejuran (PN) or hyaluronic acid boosters is covered further in Re2O vs Rejuran and the skin booster guide.
Reactions seen from the day after treatment
In the same trial, serious adverse events were counted as 0. The reactions that appeared were temporary redness and mild swelling, and they settled without treatment. If swelling increases or a feeling of heat develops, assessment is sought through the contact path you were given.
The numbers for skin measures can be confirmed in the in-depth analysis of Re2O results.
Points to cover before treatment
Asking the items below as written helps you tell whether the procedure you would receive today is the same formulation used in the trial. If the product name and mixed ingredients are left in the consultation record, you can also confirm at later follow-up that it is the same formulation.
- □ Whether the exact product name is Re2O (Elravie Re2O), and who the manufacturer and supplier are
- □ Whether hyaluronic acid, saline, and an anesthetic are mixed into today's syringe in addition to Re2O
- □ How many sessions and at what interval, and how that differs from the trial's observation period
- □ Recent facial filler, toxin, or laser; pregnancy or breastfeeding; autoimmunity; anticoagulants; active infection; severe allergy
- □ Besides expected redness and swelling, symptoms that call for immediate contact and the contact path
Frequently asked questions
Q1. Does it hurt?
The trial formulation contained an anesthetic, and clinics often use topical cream anesthesia. The published trial did not record a separate pain score.
Q2. How many sessions?
The number of sessions is set according to skin condition and goals. The trial registration information listed three sessions at one-month intervals.
Q3. How long does it last?
Confirm whether the duration mentioned in consultation is the same as the last time point the trial measured. That last time point is about five months after treatment.
Q4. Can I receive it together with Rejuran?
The materials differ, so they are not stacked on the same day. After aligning the interval and sequence, the next appointment is scheduled.
Q5. Who should postpone the appointment?
The schedule is rearranged if there is pregnancy or breastfeeding, active infection, autoimmunity, anticoagulant use, or a severe allergy. Common precautions can be confirmed in the safety information.
Results, duration, and suitability vary with individual skin condition, age, and lifestyle, and the same outcome cannot be guaranteed.
Procedures may cause temporary redness or swelling, and contraindications may apply, so please confirm these during your consultation.
This article is general information and does not replace individual medical care. Please confirm diagnosis and treatment suited to your condition during a consultation.
Sources
- Injectable particulate hADM skin-booster comparative trial in humans (PMID 41828422, PMC12985180) — Abstract and PMC full text confirmed. 20 adults aged 30~65 with moderate cheek roughness (13 women, 7 men); faces split in half; one side received Re2O 150mg mixed with non-cross-linked hyaluronic acid, saline, and lidocaine, the other side hyaluronic acid alone. Mid-dermis, automatic injector. Measurements at 1·4·8·12·16·20 weeks after treatment. Serious adverse events 0; temporary erythema and mild swelling resolved without treatment. Test article provided by the manufacturer; one author (Ju Hee Lee) advised on Elravie Re2O development. Limitations: small scale, mixed formulation, 20 weeks. No retraction or expression of concern on Europe PMC.
- Registration information for the same trial (NCT07155278) — Registration text confirmed. Lists 3 intradermal injections at one-month intervals. The paper's methods section does not specify this session count, so the body distinguishes registration information from the paper's observation period. Exclusion criteria include breastfeeding, autoimmunity, anticoagulants within 2 weeks of screening, facial aesthetic procedures within 12 months, and severe combined allergy, among others.
- Overview of injectable skin boosters (PMID 39544509) — Abstract only confirmed. Frames skin boosters as a group of procedures that inject various biomaterials to address dullness, dryness, and loss of elasticity with aging. Not a trial of the Re2O product itself. No author conflicts of interest (abstract). No retraction or expression of concern on Europe PMC.
- L&C Bio Re2O product information — Page text confirmed. Particulate acellular allogeneic dermis, Rituo 150mg, dermal structural characteristics retained. The English product listing describes finely processed hADM containing collagen, elastin, proteins, and proteoglycans. The intended-use statement is empty on this page, so it is not quoted.
- The Bio: L&C Bio–Humedix supply agreement report (2024.11.18) — Article text confirmed. Original developer L&C Bio, supplier in Korea Humedix. Statements on effects, pores, and pigmentation appear only as company description, so they are not used in the body.
Related reading
Sources
Discuss options for your current needs
We review your current health and prior procedures before explaining appropriate options and their limits.
